Want to see HK:1011 full AI Analyst Report?
1011 Stock Chart & Stats
HK$0.84
<HK$0.01(0.40%)
At close: 4:00 PM EST
HK$0.84
<HK$0.01(0.40%)
Day’s Range― - ―
52-Week RangeHK$0.30 - HK$1.20
Previous CloseN/A
Volume22.00K
Average Volume (3M)355.45K
Market Cap
HK$736.59M
Enterprise ValueHK$787.72
Total Cash (Recent Filing)HK$11.91M
Total Debt (Recent Filing)HK$334.93M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.02%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,796,563,600
10 Day Avg. Volume109,910
30 Day Avg. Volume355,448
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-1.66
Price to Sales (P/S)18.81
P/FCF Ratio-18.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe renewed revenue growth shows that product sales recovered after several weaker years, supporting the company’s ability to regain commercial traction. If maintained, a larger revenue base could improve fixed-cost absorption and provide a foundation for rebuilding profitability over the next several quarters.
Improved Gross MarginThe substantial gross-margin improvement indicates better economics on reported sales than in the prior year. Continued retention of this improvement would give the company more resources to cover operating expenses, support commercialization, and potentially narrow losses as revenue recovers.
Specialty Pharmaceutical PlatformParticipation across drug development, manufacturing, and commercialization gives the business an integrated operating model rather than dependence on a single activity. Its specialty and branded focus may support product differentiation and create opportunities to build durable commercial relationships in target markets.
Bears Say
Persistent LossesPersistent and very large losses show that revenue recovery has not yet translated into a sustainable earnings model. The deeply negative margins can consume capital, restrict reinvestment, and leave the company vulnerable if sales growth slows before operating costs are brought under control.
Stressed Balance SheetNegative equity and high debt materially reduce financial flexibility and indicate that accumulated losses have weakened the capital structure. This raises ongoing solvency and refinancing pressure, while limiting the company’s ability to fund growth or absorb further operating setbacks without external support.
Negative Cash GenerationThe return to negative operating and free cash flow indicates that the business is currently consuming cash despite its revenue rebound. If this pattern persists, funding losses and working-capital needs may require external financing, increasing execution risk and pressure on the already weak balance sheet.
China NT Pharma Group Co., Ltd. News
1011 FAQ
What was China NT Pharma Group Co., Ltd.’s price range in the past 12 months?
China NT Pharma Group Co., Ltd. lowest stock price was HK$0.30 and its highest was HK$1.20 in the past 12 months.
What is China NT Pharma Group Co., Ltd.’s market cap?
China NT Pharma Group Co., Ltd.’s market cap is HK$736.59M.
When is China NT Pharma Group Co., Ltd.’s upcoming earnings report date?
China NT Pharma Group Co., Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 181 days.
How were China NT Pharma Group Co., Ltd.’s earnings last quarter?
China NT Pharma Group Co., Ltd. released its earnings results on Aug 20, 2026. The company reported -HK$0.026 earnings per share for the quarter.
Is China NT Pharma Group Co., Ltd. overvalued?
According to Wall Street analysts China NT Pharma Group Co., Ltd.’s price is currently Overvalued.
Does China NT Pharma Group Co., Ltd. pay dividends?
China NT Pharma Group Co., Ltd. pays a Annually dividend of HK$0.035 which represents an annual dividend yield of 0.02%. See more information on China NT Pharma Group Co., Ltd. dividends here
What is China NT Pharma Group Co., Ltd.’s EPS estimate?
China NT Pharma Group Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China NT Pharma Group Co., Ltd. have?
China NT Pharma Group Co., Ltd. has 1,796,563,600 shares outstanding.
What happened to China NT Pharma Group Co., Ltd.’s price movement after its last earnings report?
China NT Pharma Group Co., Ltd. reported an EPS of -HK$0.026 in its last earnings report. Following the earnings report the stock price went down -4.688%.
Which hedge fund is a major shareholder of China NT Pharma Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1011
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China NT Pharma Group Co., Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
96.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
China NT Pharma Group Co., Ltd.
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
China Shineway Pharmaceutical Group Limited
―